Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently signed with ...

With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 ...

FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. Pharmaceutical giant Merck will close its plant in Northumberland County, Pennsylvania. According to a ...

Merck & Co. has agreed to license an investigational oral small molecule lipoprotein (a) inhibitor from Jiangsu Hengrui Pharmaceuticals in a deal potentially worth more than $2 billion to the Chinese ...

Keytruda, approved for several types of cancer, alone accounts for around 50% of the company’s pharmaceutical sales. The drug has played an instrumental role in driving Merck’s steady revenue ...

Michelle Xia represents a rising generation of biotech companies in China challenging Western giants.

Merck is planning layoffs in Pennsylvania as part of a multi-year plan to wind down operations at a manufacturing plant in the state. The pharma giant will cut 163 jobs at its Cherokee ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

Drugmaker stocks, including Pfizer (PFE), Merck (MRK), and Eli Lilly (LLY), are falling after President Trump announced that pharmaceutical tariffs may be on the way. To watch more expert insights ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Under the latest deal, Merck gets exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals’ experimental oral heart disease drug, HRS-5346. Hengrui Pharma will receive an ...

President Trump said Tuesday his administration soon would announce “major” tariffs on pharmaceuticals, adding to the tariffs he has already imposed on most goods entering the United States ...